Literature DB >> 35616579

Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats.

Wiebke Janssen1, Thomas Schwarz1, Ulf Bütehorn1, Wolfram Steinke1,2, Steffen Sandmann1, Dieter Lang1, Armin Kern1, Frank Hucke1, Michael Gerisch1.   

Abstract

Vericiguat is a soluble guanylate cyclase stimulator. The pharmacokinetics, absorption, metabolism, and excretion properties of vericiguat in rats and dogs and the distribution in rats are reported. [14C]-labelled vericiguat was studied in intact and bile duct-cannulated rats (oral and intravenous administration), and dogs (oral administration).Vericiguat reached maximum plasma concentrations at 1-3 h after oral administration. Absolute bioavailability was moderate in rats and high in dogs. Vericiguat was the most abundant component in plasma of rats and dogs.After oral administration to rats, radioactivity was widely distributed. Penetration into the brain was minimal. Elimination was rapid from most tissues in rats. Most of the radioactivity was excreted in faeces (rat: 81%, dog: 89%), while low amounts were excreted in urine (rat: 11%, dog: 4%). Clearance routes in both species were unchanged excretion and metabolism via glucuronidation and oxidative reactions. After intravenous administration to bile duct-cannulated rats, a relevant proportion of the dose (30%) underwent direct excretion into the gastrointestinal tract as unchanged vericiguat.

Entities:  

Keywords:  Absorption; and excretion (ADME); autoradiography; blood–brain barrier; distribution; metabolism; pharmacokinetics; preclinical; rats; sGC stimulator

Mesh:

Substances:

Year:  2022        PMID: 35616579     DOI: 10.1080/00498254.2022.2082899

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.997


  1 in total

1.  Study and exploration of the pharmacokinetics of traditional Tibetan medicine Ruyi Zhenbao tablets after single and long-term administration.

Authors:  Hongping Hou; Tengfei Chen; Ziying Xu; Zihui Yu; Caixia Wang; Rongxia Liu; Bo Peng; Wei Yang; Feng Li; Xiangyi Che; Bing Li; Yu Wang; Ling Song; Yunhang Gao; Zuguang Ye; Guangping Zhang
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.